Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing.

PloS one - 1 Jan 2026

Homšek Ilić Ana, Jovanović Marija, Marković Srđan, Vezmar Kovačević Sandra, Knežević Ivanovski Tamara, Kralj Đorđe, Svorcan Petar, Vučićević Katarina

Abstract excerpt

Ulcerative colitis (UC) and Crohn's disease (CD) differ in intestinal location and depth of involvement. Patients with UC who have or experienced a flare-up according to Truelove-Witts criteria (ACUS), as well as those with fistulizing Crohn's disease (FIST), may represent difficult-to-treat populations. This study investigates the phenotype- and severity-driven selection of infliximab (IFX) population...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bayes Theorem
Share to Colitis, Ulcerative

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crohn Disease

Share to Gastrointestinal Agents

Share to Inflammatory Bowel Diseases

Share to Infliximab

Share to Precision Medicine

Share to Severity of Illness Index

Source

Open in PubMed Open full text

Identifiers

PMID: 42497217
DOI: 10.1371/journal.pone.0352967
PMCID: PMC13399310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing.PMID 42497217Read ↗

The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model.Semantic proximity Read ↗

Personalizing therapy selection in inflammatory bowel disease.Semantic proximity Read ↗

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients: From Bedside to Bioinformatics.Semantic proximity Read ↗

An Interpretable PK-Informed Hybrid Model for Voriconazole Exposure Prediction: Roles of CYP2C19 Genotype and Inflammation.Semantic proximity Read ↗

Phenotypic characterisation of Crohn's disease severity.Semantic proximity Read ↗

Personalizing therapy for inflammatory bowel diseases.Semantic proximity Read ↗

To evaluate the predictive effect of vitamin D on clinical outcomes of infliximab treated Crohn’s disease patients in western ChinaSemantic proximity Read ↗

Infliximab-associated Gastrointestinal Obstruction: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (2004-2024)Semantic proximity Read ↗

Machine Learning–Driven Drug Optimization for Typhoid Fever Based on Patient ProfilesSemantic proximity Read ↗

Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three yearsSemantic proximity Read ↗

Adverse reactions associated with the use of ustekinumab in Crohn's disease treatment：an analysis based on the FAERS databaseSemantic proximity Read ↗

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.